Wilms’ tumor 1 enhances Cisplatin-resistance of advanced NSCLC  by Wu, Chen et al.
FEBS Letters 588 (2014) 4566–4572journal homepage: www.FEBSLetters .orgWilms’ tumor 1 enhances Cisplatin-resistance of advanced NSCLChttp://dx.doi.org/10.1016/j.febslet.2014.10.026
0014-5793/ 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
⇑ Corresponding authors at: Department of Tumor Biological Treatment, The
Third Afﬁliated Hospital of Soochow University, Changzhou 213000, People’s
Republic of China. Fax: +86 519 68870978 (J. Jiang). Fax: +86 25 83718836 (Y. Shu).
E-mail addresses: shu.yongqian@yahoo.com (Y. Shu), jiangjingting@suda.edu.cn
(J. Jiang).Chen Wua, Yonggong Wang b, Yang Xia b, Shaohua He c, Zhiqiang Wang b, Yijiang Chen b, Changping Wu a,
Yongqian Shu c,⇑, Jingting Jiang a,⇑
aDepartment of Tumor Biological Treatment, The Third Afﬁliated Hospital of Soochow University, Changzhou 213000, People’s Republic of China
bDepartment of Thoracic and Cardiovascular Surgery, The First Afﬁliated Hospital of Nanjing Medical University, Nanjing 210029, People’s Republic of China
cDepartment of Oncology, The First Afﬁliated Hospital of Nanjing Medical University, Nanjing 210029, People’s Republic of China
a r t i c l e i n f oArticle history:
Received 16 May 2014
Revised 19 October 2014
Accepted 22 October 2014
Available online 4 November 2014
Edited by Angel Nebreda
Keywords:
WT1
MVP
NSCLC
Chemo-resistance
Cisplatina b s t r a c t
Wilms’ tumor 1 (WT1) is an oncogene that has been correlated with tumor progression, bad
prognosis and chemo-resistance in Non-Small-Cell lung cancer (NSCLC). Here, we found that WT1
expression is signiﬁcantly higher in NSCLCs than in benign controls, and that Cisplatin-resistant
patients display a notable increase in WT1 expression following relapse. In vitro, WT1 levels were
associated with the IC50 of NSCLC cells and increased along with treatment time and dose of
Cisplatin. Furthermore, WT1 enhanced Major Vault Protein (MVP) transcription via binding to its
promoter. Therefore, WT1 may be a potential therapeutic target for solving resistance.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Lung cancer (including Non-Small-Cell lung cancer (NSCLC) and
Small-Cell lung cancer (SCLC)) remains the leading cause of cancer-
related mortality in the world [1]. Despite the advances in curative
surgery and adjuvant therapy, as well as extensive research, the
prognosis of NSCLC is still poor [2,3].
Chemo-resistance, tumor recurrence, and metastasis to distant
organs are the main contributing factors to the high mortality
and poor survival rate of this disease [4,5]. One of the common
obstacles for chemotherapy to late stage NSCLC is resistance that
reduces the curability. The investigation of this area is important
for the patients with advanced NSCLC, but far from satisfaction.
The Wilms’ tumor gene 1 (WT1) encodes a 49–52 kDa protein
with an N-terminal domain involved in RNA/protein interactions
[6]. There are four zinc ﬁnger structures in the C-terminal domain,
permitting the transcriptional function of WT1 [7]. It is an impor-
tant regulator of cell growth and development in the embryo
kidney, adult urogenital system and central nervous system [8].
Through two alternative splicing motifs of exon 5 (17 amino acid)and exon 9 (3 amino acid, KTS region), four main protein isoforms
of WT1 are designated as A (/), B (+/), C (/+) and D (+/+).
Although ﬁrst recognized as a tumor suppressor in Wilms’ tumor
(Nephroblastoma) [9], based on mounting evidence, WT1 has been
demonstrated an oncogene in a variety of malignancies including
leukemia [10], breast cancer [11] and lung cancer [12], etc. The rea-
son why WT1, the chameleon gene, plays the dichotomous role is
still unclear [13].
Although some studies have demonstrated that WT1 was asso-
ciated with chemo-resistance in leukemia [14,15], no data to date
was available elucidating the deﬁnite mechanism, which is of great
importance since WT1 has already been used as a clinical bio-
marker or leukemia and lung mesothelioma and speciﬁc peptide
vaccine was applied for treatment in Japan [16,17]. The present
study was designed to investigate the relationship between WT1
and Cisplatin-resistance, aiming to ﬁnd the molecular mechanism.
2. Materials and methods
2.1. Patients and tissue samples
The study was performed on 105 stage-IIIB and IV NSCLC (66
Adenocarcinomas and 39 Squamous cell carcinomas) and 30
patients with benign diseases (including pulmonary bullae, inﬂam-
matory pseudotumor and chronic granuloma). All specimens were
C. Wu et al. / FEBS Letters 588 (2014) 4566–4572 4567collected via diagnostic biopsy from primary tumor site before and
6–15 months after chemotherapy (biopsies were only taken once
on benign cases before treatment) between February, 2009 and
October, 2010 under a protocol approved by the Human Ethics
Committee of Nanjing Medical University. NSCLC and benign con-
trol cases were all randomly selected in bio-bank. All specimens
were histologically classiﬁed by a professional pathologist accord-
ing to the national NCCN guidelines™ for NSCLC version 3.2011
[18]. The NSCLC patients received Cisplatin-based (EP plan) pallia-
tive chemotherapy (75 mg/m2 of Cisplatin (Cisplatin for injection,
QILU Pharmaceutical, China) on day 1 through day 3, in a 3-week
cycle) without surgery and all the 135 patients participated in this
study have provided informed consents. Obvious primary tumor
shrinkage and reduce of malignant pleural effusions were consid-
ered effective treatment, which displayed in all 105 NSCLCs.
Relapsed (Cisplatin-resistant) cases were distinguished when
primary tumor enlarged, pleural effusions increased or new metas-
tasis occurred within 6–15 months (n = 35), otherwise Cisplatin-
sensitive case was deﬁned (n = 70). The median age of the patients
was 65 years (range 48–81 years) and most of them were male
(77.1%).
2.2. DNA and RNA preparation
Total RNA were extracted from tissue specimens and cells using
the TRIzol method (Invitrogen, Shanghai, China) and cDNA was
synthesized using reverse transcriptase kit (TAKARA, Tokyo, Japan)
according to the manufacturers’ protocol.
2.3. Real-time PCR (RT-PCR) for WT1 and MVP RNA expression
WT1 and MVP mRNA levels were measured by Real-time PCR
using SYBR Premix Ex Taq (TAKARA, Tokyo, Japan). WT1 and MVP
transcription values were normalized against the expression of
b-actin. Ampliﬁcation conditions, primers and probes sequences
for the WT1 and b-actin were from RT Sitaram’s work [19] and
for MVP were the same as Ulrike Stein’s article [20].
2.4. Immunohistochemistry (IHC)
IHC was performed on tissue sections with WT1 primary
antibody (1:200, 6F-H2, Millipore, Billerica, MA, USA). Slides were
evaluated semi-quantitatively (Both nuclear and cytoplasm
staining of WT1 was considered positive) and average values of
integrated optical density (IOD) were obtained from ﬁve random
ﬁelds per slide by using Image-Pro Plus software (v5.0). Every data
was detected three times at least.
2.5. Cell culture
A549 (CCL-185), H1299 (CRL-5803), Beas-2B (CRL-9609) and
293T (CRL-11268) cell lines from ATCC and A549-DDP from Acad-
emy of Military Medical Science (Beijing, China) were employed in
this study. A549, H1299, Beas-2B and A549-DDP were cultured in
RPMI 1640 medium while 293T were in DMEM high glucose med-
ium, both supplemented with 10% fetal bovine serum (Invitrogen,
Carlsbad, CA, USA). All cells were maintained in a humidiﬁed 37 C
incubator with 5% CO2.2.6. Lentivirus production, transduction and Western-blotting assay
Lentivirus production, transduction and Western-blotting assay
were carried out as previously described [21]. WT1 antibody used
in Western-blotting was the same as IHC (1:1000, 6F-H2,
Millipore).2.7. MVP interference (transient transfection)
In order to induce MVP silencing, A549 cells were transiently
transfected using Lipofectamine 2000 (Invitrogen) withMVP siRNA
(50 nM, RiboBio, Guangzhou, China) in 96-well plate (3  103
cells). Scrambled siRNA was used as control.
2.8. Cell counting kit-8 (CCK-8) assay
Cells were seeded into 96-well plates and the viability was
assessed by CCK-8 assay (Beyotime institute of biotechnology,
Shanghai, China) after Cisplatin exposure. The absorbance of each
well was read on a spectrophotometer (Thermo) at 450 nm
(A450).At least three independent experiments were performed.
2.9. Real-time PCR array
Total RNA was extracted from A549, A549-WT1, A549-shWT1,
H1299, H1299-WT1 and H1299-shWT1, reverse transcribed to
cDNA and then Real-time PCR was carried out using the RT2 Proﬁl-
er™ PCR Array Human Cancer Drug Resistance & Metabolism
(SuperArray Bioscience, Frederick, MD, USA) in an ABI PRISM7900
system (Applied Biosystems, California, USA).
2.10. Chromatin immunoprecipitations (ChIP)
WT1-D gene was cloned into pcDNA3.1 plasmid (gift from D.
Beicheng Sun) and named pcDNA3.1-WT1, with which A549 cells
were transfected. A total of 3  106 WT1-transfected A549 cells
were used for ChiP analysis using a protocol we described
previously [19]. The PCRs containing 3 ll immunoprecipitated
DNA or input chromatin, primers and Tag enzyme (Applied Biosys-
tem) in 50 ll volume were performed with denaturation at 95 C
for 10 min, 35 cycles (95 C for 30 s, 57 C for 30 s and 72 C for
45 s) and a ﬁnal extension at 72 C for 10 min. The primers of
MVP promoter were: P1F 50-gacctcacctggatggtctg-30, P1R 50-ggaga-
gacagccttcgcttt-30; P2F 50-aacccagcctggatcatcac-30, P2R 50-caggac
tgtgacagaggcg-30. The PCR products were validated via agarose
gel electrophoresis.
2.11. Luciferase reporter assay
A dual-luciferase reporter assay was performed to investigate
the transcriptional regulation of MVP by WT1-D. Via web tool
http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promo.cgi?dirDB
=TF_8.3&calledBy=alggen, four potential WT1 binding sites were
predicted. As a result of overlapping, we considered the ﬁrst two
binding sites together as one named -770 (770 bp ahead of tran-
scriptional initiating site) and the last two named -172 (172 bp
ahead of transcriptional initiating site). The structures of wild-type
or mutated MVP promoters (-770-Mut & -172-Mut) were synthe-
sized artiﬁcially and illustrated in Fig. 3D. Products were validated
via agarose gel electrophoresis, and cloned into the luciferase
reporter vector (Promega, Madison, WI). WT1-D gene was cloned
into pcDNA3.1 plasmid (gift from D. Beicheng Sun) and named
pcDNA3.1-WT1 (marked as ‘‘N’’). A549 cells were seeded into 24-
well plates and co-transfected withWT1-siRNA (pooled siGENOME
SMART pool WT1 siRNA (50 nM/well), Dharmacon, Chicago, IL,
USA), marked as ‘‘.’’) or pcDNA3.1-WT1-empty, control siRNA
(Dharmacon, Chicago, IL, USA, marked as ‘‘-’’)and empty pcDNA3.1
(marked as ‘‘-’’) as control, respectively, and luciferase reporter
vectors using Lipofectamine™ 2000 (Invitrogen), following the
manufacturer’s instructions. Zero, 6, 12, 24 and 48 h after incuba-
tion, ﬁreﬂy and Renilla luciferase activity was measured with the
dual luciferase reporter assay system (Promega). All results were
gained through three independent experiments.
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Statistical analysis was performed using GraphPad Prism (ver-
sion 5.01, GraphPad Software, Inc., CA, USA) statistical software.
The Student’s t-test was used to analyze signiﬁcance between
independent groups. The correlation test was used to analyze the
correlation between WT1 and MVP. The v2 test was used to test
the signiﬁcance of observed differences in proportions except
when the cells size was <5 (Fisher’s exact tests). The signiﬁcance
was accepted as P < 0.05.3. Results
3.1. WT1 was higher expressed in NSCLC and increased in Cisplatin-
resistance patients
A total of 210 NSCLC (2 for each patient) and 30 benign samples
(1 for each patient) were collected from 135 patients. The IHC
showed that WT1 staining was stronger in NSCLCs than benign
controls and signiﬁcant enhanced when Cisplatin-resistance
occurred. Three classic cases (one for benign, Cisplatin-sensitive
and Cisplatin-resistant, respectively) were shown in Fig. 1A–E: in
the benign case, WT1 was almost negative (Fig. 1A); in Cisplatin-
sensitive case, WT1 staining was nearly the same before and after
Cisplatin administration (Fig. 1B and C); however, in Cisplatin-
resistance one, WT1 was signiﬁcantly higher at the time point of
relapse (Fig. 1D and E). Furthermore, in accordance with IHC result,
WT1 mRNA level was higher in NSCLC than control (P < 0.0001,Fig. 1. WT1 expression in NSCLC or benign diseases WT1 staining was almost negative on
(B) and after chemotherapy (C) and Cisplatin-resistant ones before chemotherapy (D), b
were all 50 lm in length; Accordingly, RNA level of WT1 was signiﬁcantly higher in NSC
while no signiﬁcant change was identiﬁed in Cisplatin-sensitive ones (G).Fig. 1F) and only in Cisplatin-resistant patients, WT1 was increased
(P < 0.0001, Fig. 1H), while no signiﬁcant change was identiﬁed in
Cisplatin-sensitive ones (P = 0.3059, Fig. 1G).
Our 105 NSCLCs were divided into two groups using median
RNA level of WT1 before and after chemotherapy (before chemo-
therapy, median = 4.3606; after chemotherapy, median = 5.6559)
as threshold. As shown in Table 1. WT1 mRNA level was not corre-
lated with age, gender, smoke history, histology and pathological
stage in our NSCLC population.
3.2. WT1 promoted Cisplatin-resistance
In vitro, as shown in Fig. 2A–D, the resistant phenotype of both
A549 and H1299 cells could be signiﬁcantly enhanced by WT1
over-expression and evidently suppressed by WT1-shRNA, which
was conﬁrmed by IC50 calculation: A549-WT1 (4.477 lg/ml) >
A549 (3.665 lg/ml) > A549-shWT1 (2.153 lg/ml); H1299-WT1
(4.042 lg/ml) > H1299 (3.140 lg/ml) > H1299-shWT1 (1.397 lg/
ml). WT1 was all detected in A549, A549-DDP and Beas-2B,
however, the protein levels were not consistent with IC50s
(Fig. 2E and F): protein level: A549-DDP > A549 > Beas-2B;
IC50: A549-DDP (17.365 lg/ml) > Beas-2B (4.892 lg/ml) > A549
(3.665 lg/ml).
In both A549 and H1299, the WT1 protein level was heightened
with the Cisplatin exposure time increased (Fig. 2I and K). WT1
increased with the concentration gradient of Cisplatin (Fig. 2J
and L). The grayscale value of western-blot was illustrated in Sup-
plement Fig. 1. A549-DDP, the IC50 also drop from 17.365 lg/ml to
10.53 lg/ml (Fig. 2G and H).specimens of benign disease (A), weak positive on Cisplatin-sensitive NSCLC before
ut strong positive on Cisplatin-resistant ones when repalse occurred (E); The bars
LC (F) and only in Cisplatin-resistant patients, WT1 was increased after relapse (H)
Table 1
Correlation between WT1 status (before and after chemotherapy) and clinical characteristics in patients with NSCLC (n = 105).
Characteristics All patients Before chemotherapy After chemotherapy
WT1 high expression
(Pmediana)
WT1 low expression
(<mediana)
P WT1 high expression
(Pmedianb)
WT1 low expression
(<medianb)
P
n 105 53 52 52 53
Age (years) 0.855 0.855
Median (range) 65 (48–81) 65 (48–81) 66 (48–80) 65 (48–81) 66 (48–80)
Gender 0.148 0.246
Male 81 (77.1%) 44 (41.9%) 37 (35.2%) 43 (41.0%) 38 (36.1%)
Female 24 (22.9%) 9 (8.6%) 15 (14.3%) 9 (8.6%) 15 (14.3%)
Smoke 0.136 0.638
Yes 83 (79.0%) 45 (42.9%) 38 (36.1%) 40 (38.1%) 43 (41.0%)
No 22 (21.0%) 8 (7.7%) 14 (13.3%) 12 (11.4%) 10 (9.5%)
Histology 0.181 0.421
Adenocarcinoma 66 (62.9%) 30 (28.6%) 36 (34.3%) 35 (33.3%) 31 (29.5%)
Squamous cell
carcinoma
39 (34.1%) 23 (21.9%) 16 (15.2%) 17 (16.1%) 22 (20.1%)
Pathological stagec 0.946 0.06
IIIB 71 (67.6%) 36 (34.3%) 35 (33.3%) 40 (38.1%) 31 (29.5%)
IV 34 (32.4%) 17 (16.2%) 17 (16.2%) 12 (11.4%) 22 (21.0%)
a Median = 4.3606.
b Median = 5.6559.
c Pathological stage was based on NCCN (National Comprehensive Cancer Network) Guidelines™ version 3.2011 Non-Small Cell lung cancer.
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pathway
A variety of genes were screened out afterWT1 over-expression
and down-regulation via the PCR array focusing on human Drug
Resistance & Metabolism pathway (Supplement Tables 1 and 2).
A total of 10 genes from A549 and 6 genes from H1299 whose var-
iation were larger than 4-folds were displayed in Fig. 3A and B.
Only MVP and MSH2 were the common ones and MVP increased
the most (A549: 8.87-folds; H1299: 4.21-folds). The result of Wes-
tern-blot conﬁrmed that in A549, MVP protein was closely con-
certed to WT1 (Fig. 3C).
3.4. WT1 enhanced MVP transcription via direct binding to the
promoter
MVP was demonstrated to be associated with chemo-resistance
and our interference experiment showed a decreased IC50 of A549
cells after MVP silencing (Fig. 3D). The basal level ofMVP protein in
A549, H1299 and A549-DDP cells were shown in Supplement
Fig. 2. To demonstrate the functional link between WT1-D and
MVP, we performed ChIP/PCR analysis and luciferase reporter assay
in A549 cell line with pcDNA3.1-WT1 plasmid and WT1 siRNA for
transient transfection experiments. As shown in Fig. 3E, a single
band was observed when chromatins from WT1-transfected
A549 cells were immunoprecipitated with WT1 antibody, but not
when rabbit IgG antibody was used. By ChIP/PCR assay we could
demonstrate direct binding of WT1 to MVP promoter. The lucifer-
ase activity represented MVP transcription was detected enhanced
after WT1-D over-expression and oppositely, weakened after WT1
silencing both with time increasing (Fig. 3G and H). In A549 cells
with -770-Mut or -172-Mut MVP promoter, the luciferase activity
attenuated signiﬁcantly, comparing to the one with wild-type pro-
moter. Furthermore, the luciferase activity weakened the most in
cells with promoter carrying mutations of both sites. On the con-
trary, -770-Mut or -172-Mut could evidently whittled away the
decrease of luciferase activity by WT1 siRNA in A549 transfected
with wild-type promoter. When both sites were mutated, the lucif-
erase activity was nearly normalized to basic line, hardly showing
any effect of WT1 siRNA (Fig. 3I).4. Discussion
A large portion of NSCLC patients lose their chances of surgical
resection owing to the difﬁculty of early diagnosis, leaving chemo-
therapy the most widely used and effective treatment. However,
Chemo-resistance has set huge obstacle to NSCLC patients and doc-
tors. The elucidation of the mechanisms of resistance is crucial for
improving treatment outcome, especially for selecting and custom-
izing chemotherapy.
Initially in genitourinary system, WT1 was discovered as a
tumor suppressor gene [8]. The role of WT1 outside of the genito-
urinary system remains controversy despite of large number of
functional studies [22,23]. Over-expression and mutations of WT1
gene have been reported in different types of cancer, such as acute
myeloid leukemia (AML) [24], ovarian cancer [25] and lung cancer
[26]. Recently, WT1 was reported involved in inducing anti-
estrogen resistance in human breast cancer cells [27], insensitivity
to imatinib in leukemia cells [15] and doxorubicin in human hepa-
tocellular carcinoma (HCC) [28]. Furthermore, Candice McCoy has
demonstrated that WT1 could inhibit 12-O-tetradecanoylphorbol-
13-acetate (TPA) activation of MDR1 and itself could activate
MDR1 [29], which probably expounded the mechanism of resis-
tance in leukemia treatment. In this study, we discovered a rela-
tionship of WT1 with resistance of Cisplatin-based chemotherapy,
found that WT1 would increase along with Cisplatin doses and
exposure time and demonstratedWT1 could promote the Cisplatin
resistance of NSCLC cells by directly regulation of MVP.
Chemo-resistance is a polygene involved and multi-stage cas-
cade. Studies have revealed that inactivation of tumor suppressive
factors, DNA repairs genes and cell cycle regulators were essential
for resistance [30–33]. MVP encodes the major component of the
vault complex and may play pivotal role in chemo-resistance, via
regulating MAP kinase, JAK/STAT and phosphoinositide 3-kinase/
Akt signaling pathways [34–36]. Min Han et al. reported that
down-regulation of MVP may allow the intracellular drug to enter
the nucleus, which eliminated one of the best characterized barri-
ers to chemotherapy [37]. Losert et al. demonstrated that in HCC,
MVPwas a key marker of sensitivity, suggestingMVP a novel player
in resistance against EGFR inhibition [38]. Izquierdo et al. has
clariﬁed that MVP owned a greatest individual value as a marker
Fig. 2. WT1 could regulate Cisplatin-resistance of A549, H1299 and A549/DDP cells. Western-blot showed efﬁcient over-expression or silencing of WT1 via lentivirus in both
A549 (A) and H1299 (C); IC50 of A549 increased in A549-WT1 and decreased in A549-shWT1 (B, IC50: A549-WT1 (4.477 lg/ml) > A549 (3.665 lg/ml) > A549-shWT1
(2.153 lg/ml)); Similarly, IC50 of H1299-WT1 was signiﬁcantly higher than H1299 and H1299-shWT1 (D, IC50: H1299-WT1 (4.042 lg/ml) > H1299 (3.140 lg/ml) > H1299-
shWT1 (1.397 lg/ml)); Western-blot compared WT1 protein of A549-DDP, A549 and Beas-2B (E) and IC50 of A549-DDP (17.365 lg/ml) was signiﬁcantly higher than Beas-2B
(4.892 lg/ml) and A549 (3.665 lg/ml) (F); In A549-DDP, after WT1 silencing (G), IC50 decreased from 17.365 lg/ml to 10.53 lg/ml (H). In both A549 and H1299 cells, WT1
was heightened with Cisplatin exposure time (I) and (K) and dose (J) and (L) increased.
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result supported the previous ﬁndings. On the contrary, in nasal
NK/T cell lymphoma, WT1 or P53 over-expression were unlikely a
regulatory protein for the expression of MRP and MVP [41]. In
our study, WT1 was identiﬁed to regulate MVP transcription via
two binding motifs on the promoter region, which was incongru-
ent to the ﬁndings in nasal lymphoma. Furthermore, not only
RNA, but also protein of MVP, the ﬁnal actor of function, could be
regulated by WT1, which supported the ﬁnding via IHC that the
WT1 protein staining was consistent with Cisplatin-resistance in
NSCLC samples. One possible explanation to this incoherence was
that WT1 had a dichotomous function in a tissue-dependant man-
ner. As a result, the current study could only illustrate the impor-
tance of WT1 on chemo-resistance within limits of NSCLC. The
biological and pathological function of WT1 in general, however,
remains an unsolved mystery.
In this study, WT1 protein level was not consistent with IC50
value among A549-DDP, A549 and Beas-2B cells. It perhaps
because Beas-2B, as a normal lung epithelia cell line, was not as
sensitive as cancer cells to Cisplatin. Despite of higher WT1 level
in Beas-2B than A549, the insensitivity of Beas-2B probably was
induced by molecules other than WT1, which was not the main
point in this study.
A549, A549-DDP and Beas-2B cells represent sensitive, resistant
and normal cells in our study. The IC50 of Beas-2B was between
A549 and A549-DDP (Fig. 2E), which is of great clinical signiﬁ-
cance: in the initial of chemotherapy when most cancer cells were
sensitive to Cisplatin, small dose of chemo was probably effective
enough for treatment and relatively safe for normal tissue; how-
ever, when resistance occurred, high dose of chemo that could killcancer cells was also too toxic for normal tissue. As a result, sensi-
tizing the resistant cells was important for keeping the therapeutic
window, which may reduce the side effects and complications.
Since 1972 when Knudson and Strong ﬁrst discovered, located
and named WT1 [42], many of its downstream, upstream and
partner genes have been found. As summarized in Supplement
Table 1 and illustrated in Fig. 3A, genes that were signiﬁcantly
up-regulated after WT1 over-expression were nearly all providing
or enhancing multi-drug resistance (e.g., MVP, HIF1A and BRCA1);
the ones that were down-regulated along withWT1 silencing were
involved in drug metabolism (e.g., FOS and PPARD). Although after
WT1 over-expression (down-regulation), not all the changes of the
genes in the PCR array gravitated towards resistance (sensitivity),
the general trend was obvious, suggesting the change in chemo-
resistance should not be attributed to alternations of one or a small
quantity of genes.
In summary, we identiﬁed that WT1 expression was higher in
NSCLC than normal tissues and associated with Cisplatin-
resistance in 105 NSCLC patients. WT1D, a +KTS WT1 isoform, par-
ticipated in RNA metabolism and played a role as transcriptional
regulator of genes involved in Cisplatin resistance. Via direct
binding to the promoter, WT1D could promote MVP and improve
NSCLC Cisplatin-resistance. Further work would be required to
demonstrate whether this is a speciﬁc effect of WT1D or is a gen-
eral function for all major WT1 isoforms.Conﬂict of interest
The authors declared no conﬂict of interest.
Fig. 3. WT1 could enhanceMVP transcription via direct binding to the promoter. A total of 10 genes in A549 (A) and 6 genes in H1299 (B) whose variation larger than 4-folds
were displayed; Western-blot validated that protein level of MVP was correlated with WT1 in A549 (C); CCK-8 result conﬁrmed thatMVP silencing would lead to decrease of
IC50 (D). Chromatin immunoprecipitation (ChIP)/PCR assay after forced overexpression of WT1-D in A549 cells showed direct binding of WT1-D on MVP promoter. The
location and size for each PCR product are illustrated below (E). The structures of wild-type or mutated MVP promoters (-770-Mut & -172-Mut) were synthesized artiﬁcially
and illustrated (F); The luciferase activity in A549 rose after WT1 over-expression (G) and fell after silencing (H) with time increasing; The enhancive (attenuative) effect of
WT1 on MVP transcription was crippled when MVP promoter was mutated on either -770-Mut or -172-Mut and decreased (increased) to baseline when both sites were
mutated (I).
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